Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Functional beverages — drinks producers tout as having health benefits because they have been infused with bioactive compounds.
After nearly 3,000 years, the business of the Olympics is ripe for disruption. Could performance enhancing drugs shake up the games?
The World Health Organization has declared mpox to be a public health emergency, and pharmaceutical and healthcare winners have emerged.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Mars announced on Wednesday that it has agreed to buy snack maker Kellanova, a spin-off from Kellogg’s, for a mouth-watering $35.9 billion.
For Starbucks chief Laxman Narasimhan, the daily grind is over. The embattled coffee chain named Chipotle CEO Brian Niccol his successor.
As Paramount moves under the control of Skydance Media, current leadership is undergoing a campaign to realize half a billion in savings.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
As the ISS is decommissioned, several space station projects are in the works, but a business model may be the final frontier.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
The Integrity Council for the Voluntary Carbon Market issued some new guidelines on what types of carbon credits it can rubber-stamp.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.